CpG Blocks Immunosuppression by MyeloidDerived Suppressor .
· Purpose: The Tolllike receptor (TLR) 9 ligand CpG has been used successfully for the immunotherapy of cancer. Chronic CpG appliion in tumorfree hosts leads, however, to the expansion of myeloidderived suppressor cells (MDSC), which can cause Tcell suppression and may thus hamper the development of an effective immune response.
![whatsapp](/images/whatsapp.png)